Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma

Subject Area: Pharmacology
David König; Jürgen Hench; Stephan Frank; Laura Dima; Ivana Bratic Hench; Heinz Läubli
Pharmacology (2022) 107 (7-8): 433–438.

High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.

Keywords: Tumor agnostic, Targeted therapy, Precision medicine, Brain cancer, Glioblastoma
BUY THIS ARTICLE

 

© thepharmacology.org